Whoop Continues Targeted Blood Testing Push With New Specialized Panels

New $299 panels deepen the company’s foray into clinical-grade insights, building on its Advanced Labs platform and broader ambitions in continuous, personalized care

Whoop is expanding its push into clinical-grade health insights with the launch of Specialized Panels, a new suite of targeted blood tests designed to deliver deeper, more personalized data across key areas of health.

The Boston-based human performance company’s latest offering builds on its Advanced Labs platform, which debuted in 2025 following a partnership with Quest Diagnostics. That initial rollout combined blood testing with continuous wearable data, allowing users to track biomarkers like cholesterol, hormone health and blood glucose alongside metrics captured by the Whoop device. The feature drew strong early demand, with more than 350,000 members joining the waitlist after its preview, as the company positioned itself toward becoming a broader “health operating system.”

With Specialized Panels, Whoop is moving toward more focused analysis, reflecting a wider trend in wearables toward clinical integration and continuous care.

Each panel, priced at $299, analyzes between 75 and 89 biomarkers across five categories: heart health, performance, metabolic health, women’s health and men’s health. The tests are available as one-time purchases, do not require a subscription or prior comprehensive panel and are eligible for FSA/HSA spending.

“The response we’ve seen since launching Advanced Labs has been exceptional,” said Alex Vannoni, Head of Healthcare Product at Whoop. “Specialized Panels allow us to take the experience further. We’re empowering our members to choose more bespoke panels that address areas of interest or concern.”

Early data from Advanced Labs highlights the potential demand for more targeted testing. According to Whoop, 22% of its highly active member base shows signs of metabolic dysfunction, while nearly 30% have underlying cardiometabolic risk factors, often without prior awareness.

Whoop’s move also comes as other wearable companies expand into lab testing and more integrated health ecosystems. Oura, for example, introduced its own Health Panels in collaboration with Quest Diagnostics, offering members access to testing across roughly 50 biomarkers with results delivered directly in-app and paired with AI-driven insights and personalized recommendations. At the same time, wearable data is increasingly being integrated into clinical care models, with Vida Health partnering with Oura to bring real-time biometric data into its cardiometabolic programs, giving providers continuous visibility into signals like sleep, heart rate variability and resting heart rate alongside clinical and behavioral data.